Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Filters applied: . Clear all
Page 1
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J. Martinez-Useros J, et al. Among authors: senin c. BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965. BMC Cancer. 2014. PMID: 25515240 Free PMC article.
PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I, Manso R, Rincón R, Caramés C, Senin C, Borrero A, Martínez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Cristóbal I, et al. Among authors: senin c. Mol Cancer Ther. 2014 Apr;13(4):938-47. doi: 10.1158/1535-7163.MCT-13-0150. Epub 2014 Jan 21. Mol Cancer Ther. 2014. PMID: 24448818 Free article.